EGFR and neoplasm: Gefitinib is a reversible first-generation EGFR-TKI that acts as an ATP competitive inhibitor and binds to the tyrosine kinase pocket of EGFR, thereby inhibiting EGFR phosphorylation and its downstream signaling pathway, discouraging the growth and inducing apoptosis of tumor cells (Morin, 2000).